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Summary Recent biochemical and pharmacological findings concerning tamoxifen (TMX) have proven that
both the unchanged drug and the main metabolites, N-desmethyltamoxifen (NDT) and 4-hydroxytamoxifen
(4OHT) are biologically active. An HPLC method based on on-line post-column UV irradiation with
fluorescence detection is described. Optimized conditions allowed complete and rapid separation of TMX
40HT, NDT and two other recently reported metabolites, Y and Z. This method was applied to plasma and
cytosol drug and metabolite analyses. In plasma, from the moment of initial drug administration until the
steady state (after 1 month or more of continuous oral TMX treatment), the values of NDT to TMX ratios
were completely reversed: 22 to 215 in mean %, P<0.01. The presence of metabolites Y and Z is significant.
40HT, hardly detectable at the first dose, was measured at the steady state with high interpatient variability.
It is hypothesized that metabolite evolution with time may be due to auto-induction of drug metabolism. In
cytosols, which were all obtained during continuous TMX treatment, the ratios between TMX and
metabolites were comparable to those observed in plasma, but with greater interpatient variability. Metabolite
Y was not detectable in cytosols. This variability was not linked to the levels of cytosolic oestradiol receptors
before initiation of treatment.
Recent literature has provided new insights into the
molecular pharmacology of tamoxifen (TMX), its main
metabolites, N-desmethyltamoxifen (NDT), 4-hydroxy-
tamoxifen (40HT), and its more recently reported metabo-
lites Y (Jordan et al., 1983) and Z (Kemp et al., 1983).
Although their biochemical identity has not yet been
established, antioestrogen binding sites, which differ from
oestradiol receptors (ER), are the subject of current investi-
gation (Sutherland & Murphy, 1980; Sudo et al., 1983;
Ferno & Borg, 1985). The binding affinity of E2, TMX,
NDT, and 40HT relative to ER warrants increased study
(Borgna & Rochefort, 1980; Fabian et al., 1981; Reddel et
al., 1983; Miller et al., 1984). These investigations have
shown that 40HT, due to its preponderant affinity for ER,
may play a critical role in the overall antioestrogenic action
of the triphenylethylene derivatives. These studies have
emphasized the need for an analytical method allowing
simultaneous measurement of TMX and its main metabolites
not only in plasma, but also in tumoral tissue in order to
examine the possible relationship between distribution of
TMX and/or metabolites and tumour response. Among
recently developed methods, HPLC seems the most adequate
since it is both sensitive, selective and suitable for routine
analysis (Brown et al., 1983; Camaggi et al., 1983). Improve-
ment of analytic parameters has resulted in original
conditions compatible with sensitive and selective deter-
mination of TMX, NDT, 40HT, Y and Z. Application to
individual pharmacokinetics and cytosol drug assays is
presented for breast cancer patients under TMX treatment.
Materials and Methods
Reagents
Tamoxifen (ICI 46 474), N-desmethyltamoxifen (ICI 55 548),
4-hydroxytamoxifen (ICI 79 280), and metabolites Y (ICI
142 269) and Z (ICI 142 268) were provided by ICI
(Pharmaceuticals Division, Macclesfield, UK). The internal
standard, clomifene (CMF), was provided by Merrel Labora-
tories (Paris, France). Stock solutions of drugs (100ljgml-1)
were prepared in absolute ethanol and stored in polyethylene
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flasks at -20°C. Working standards were prepared by
appropriate dilutions of these stock solutions in polyethylene
tubes. Acetonitrile for HPLC, and Butanol-1 PA were
obtained from MERCK (Darmstadt, FRG). Methanol,
diethyl ether, and hexane (all Normapur) were purchased
from Prolabo (Paris, France). Phosphoric acid 85% was
from Carlo Erba (Milan, Italy); KH2PO4 Rectapur was from
Prolabo (Paris, France). Silicone solution was from Serva
(Heidelberg, FRG).
Apparatus
Figure 1 details the system used for chromatographic
separation, on-line photocyclisation, spectrofluorimetric
detection, and recording. A 6000 A pump, U6K injector,
and RCM 100 column compression module were supplied by
Waters Associates (Milford, MA, USA). A spectrofluori-
meter SFM 25 (Kontron, Zurich, Switzerland) was equipped
with 10 and 15 nm slits; voltage was set at 600V and the
gain between 0.2 and 0.5. A Hewlett-Packard 3390A
integrator (Arondale, PA, USA) was used for
chromatographic recording. The UV on-line photocyclisation
system was derived from a previously described system
(Camaggi et al., 1983): at the outlet of the column, a 6.5 m
long Teflon capillary tube (0.35mm ID, 1.5mm OD) was
arranged in 7 superposed circonvolutions (20cm diameter),
with a Philips HPK 125 watt high pressure mercury lamp
located in the centre. This irradiation system was enclosed in
a wooden box with forced ventilation (20 x 30 x 40cm).
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Figure 1 Description of the chromatographic system with on-
line UV irradiation and spectrofluorimetric detection.
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Chromatographic conditions
Mobile phase KH2PO4 10-2 M/20%; H3PO4 0.3 M/10%;
H2O/28%; CH3CN/42%.
Columns The performance of a conventional stainless steel
column (Zorbax CN 4.6 mm x 25 cm, Dupont Wilmington,
DE, USA), flow rate 2.8 ml min- 1, was compared to that of
a radially compressed column (Rad Pak Cartridge CN 10 jm
100-8, Waters Associates, Milford, MA, USA), flow rate
2.5mlmin-1. Absorption and emission spectra were recorded
for MTX, 4OHT, NDT, Y and Z (I jgml - by stop-flow
after on-line UV irradiation). Optimal routine conditions
were: ex=258nm and em=378nm.
Sample preparation
Oneml blood samples were obtained in EDTA tubes. All
glass tubes used for extraction were siliconated before use.
The different types of plasma extractions described in the
literature were compared:
Organic extraction Diethyl ether (Golander & Sternson,
1980); hexane-butanol 2% (Brown et al., 1983). Plasma
(0.5ml), spiked with 2 jg clomifene, was extracted twice with
4vol of organic solvant each time. The organic phases were
combined after centrifugation (2000rpm, 4°C, 10min) and
dried under N2 at 37°C. The dried residue was reconstituted
in 250 jil of methanol, centrifuged (2000rpm, 4°C, 10min),
and I0-I00,jl were injected.
Sep pak C18 extraction (Waters Associates, Milford, MA,
USA) (Camaggi et al., 1983) One ml plasma, spiked with
4 jg clomifene, was treated with 2 ml water/methanol (1:1).
After vortexing and centrifugation (2000rpm, 4°C, 10min),
the supernatant was filtered through the SEP PAK cartridge
previously activated by the passage of 3 ml of methanol
followed by 3 ml of H20. Successive elutions were performed
with 5ml H20, lml H20. CH3CN 1:1, and 0.5ml CH3CN.
All eluates were discarded. The eluate from the last elution
(5ml 0.3M phosphoric acid in CH3CN) was concentrated
under vacuum (Buchi Rotavapor R). The dried residue was
reconstituted with 250pl of methanol and 50pl were injected.
Results
Choice of the column system
Figure 2 shows the HPLC profiles of TMX and its main
metabolites separated by the conventional stainless steel
column which gave the best performances. The values of the
capacity factor K' were as follows: 4OHT, 2.79; Z, 4.07;
NDT, 4.93; TMX, 5.71; Y, 7.36; CMF, 7.50.
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Figure 2 HPLC profile of pure compounds 4OHT (1), Z (2),
NDT (3), TMX (4), and T (5), Internal Standard (6). 25,l of a
200 ngml 1 solution of each compound injected HV =600V gain
=0.5.
reproducibility (spiked plasma at 100 ngml1, 6 points) was
respectively (coefficient of variation, %): 4OHT, 10 and 11;
Z, 7 and 11; NDT, 2 and 10; TMX, 3 and 14; Y, 3 and 7.
Plasma levels in treatedpatients
Figure 3a gives the profile of a blank plasma and Figure 3b
the plasma profile of a patient under TMX treatment.
Quantitatively, NDT appears the major metabolite; 40HT,
Y and Z were formed to lesser degrees.
a
Start
L
0 5 10
Time (minutes)
b
Choice ofthe extraction process
Recoveries were low (close to 30%) with cartridge extraction.
Organic extraction was better: higher recuperation was
obtained with 2% hexane-butanol, but the cleanest blank
plasma resulted from diethyl ether extraction. This last
extraction process was retained, and gave the following
recoveries (spiked plasma at 100 ngml- 1): 4OHT, 68%; Z,
62%; NDT, 92%; TMX, 67%; Y, 95%; CMF, 85%.
Linearity, sensitivity, reproducibility
When the mean peak height (Y, mm) is considered as a
function of spiked plasma extracted in triplicate by diethyl
ether (x =5, 10, 20, 50, 100 ng ml 1), regression lines
(y = a +bx) were obtained with r2 at 0.99. The limit of
sensitivity 2.5 times the baseline height for 500pi of diethyl
ether extracted plasma (100 jl injected) was 2 ngml1 (0.5 ng
injected) for 40HT, Z and TMX, and 1.5ngml-1 (0.3ng
injected) for NDT and Y. Intra- and inter-assay
Start
3
Lj¶
Stop
I a a
0 5 10
Time (minutes)
Figure 3 Plasmatic profiles HV =600 V gain=0.5. (a): blank
plasma; (b) extracted plasma of a patient under treatment. For
details see Materials and methods. Peaks 1-6 as described in
Figure 2.
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Table I presents the main pharmacokinetics data for a
single dose of TMX and at the steady state for 6 patients.
40HT was hardly detectable at the first dose. By contrast,
40HT was present at the steady state (1 month or more).
Metabolites Y and Z followed the same mode of evolution,
and represented significant metabolites during chronic
treatment. High inter-patient variability was seen in both
TMX and metabolite plasma levels, particularly at the steady
state. It is striking to note that the NDT to TMX ratios
were completely reversed from the first dose (mean=22%)
to the steady state (mean=215%), P<0.01. There was a
similar but not significant, trend for metabolite Z. The
proportion of metabolite Y did not vary, on the average,
between the first dose and the steady state.
Drug levels in tumour cytosol
Table II lists the cytosol in values of TMX and its main
metabolites for 5 patients during continuous treatment.
Globally, the cytosol distribution of TMX and metabolites
reflected the general profile in serum (excess of NDT),
although metabolite Z represented a higher percentage than
in serum. Metabolite Y was never detectable. There was no
apparent link between the ER level and the intra-cytosol
concentration of TMX and metabolites.
Discussion
The increasing clinical use of the antioestrogenic compound
TMX has stimulated experimental efforts to elucidate its
complex mechanism of action (cf. review of Furr & Jordan,
1984). Sutherland and Murphy (1980) investigated the
comparative binding of 3H E2 and 3H TMX in ER positive
and negative cytosols of human breast cancer carcinomas;
their results support the evidence for the presence of anti-
oestrogen binding sites which E2 was unable to saturate in
binding. Certain recent investigations have confirmed the
existence of such specific triphenylethylene binding sites
(Miller et al., 1984) whereas others do not (Raam et al.,
1983; Ferno & Borg, 1985). The relative affinity of E2,
TMX, NDT, 4OHT and Y for ER has been extensively
explored, and general consensus is observed in the literature
(Borgna & Rochefort, 1980; Fabian et al., 1981; Jordan et
al., 1983; Reddel et al., 1983; Miller et al., 1984; Tate et al.,
1984). Thus, 4OHT appears to be equally or more potent
than E2 for binding, whereas TMX, NDT and Y are bound
with a lesser affinity. The observation that the drug concen-
tration may condition the mode of action of triphenyl-
ethylene derivatives is an interesting acquisition (Reddel et
al., 1985). In brief, on a submicromolar level, TMX and its
metabolites can inhibit cellular proliferation (Reddel et al.,
1983; Briand & Lykkesfeldt, 1984; Taylor et al., 1984); for
other cellular systems, TMX and its metabolites can
stimulate cell proliferation (Reddel & Sutherland, 1984).
Above micromolar level, the antioestrogens are cytotoxic,
the order of potency being NDT>40HT>TMX (Reddel et
al., 1983). All of these concepts require clinical confirmation
and this necessitates a sensitive and specific method for
analysis of TMX and related metabolites. In the present
method, we adopted the principle of on-line post-HPLC
Table I Pharmacokinetics parameters at the first dose and steady state for breast cancer patients treated by adjuvant hormone therapy with
TMX only
First Dose (30mg) Steady State (I month or more with daily oral dose of30mg)
C max, ngml- 1 ngml-1
NDT0 NDT0
Patients TMX 40HT NDT Y Z % TMX 40HT NDT Y Z TM %
LIS 49.1 ND 10.8 1.5 ND 22 74.0 3.4 193.1 20.7 24.5 261
TOU 46.0 ND 11.5 1.8 3.3 25 152.6 13.5 352.0 19.9 39.5 231
SPA 73.9 ND 11.9 7.6 1.9 16 120.0 6.5 258.0 40.0 50.0 215
RAM 90.0 1.5 10.8 11.8 6.3 12 77.5 2.9 96.2 14.7 7.4 124
PIS 66.0 ND 17.8 ND 2.2 27 147.8 6.6 214.8 28.4 33.3 145
RAY 74.8 ND 21.7 11.1 ND 29 298.9 5.9 941.8 83.9 176.2 315
Mean 66.5 14.1 5.6 2.2 22 145.1 6.5 342.6 34.6 55.1 215
(s.d.) (16.9) (4.5) (5.2) (2.3) (7) (82.4) (3.8) (305.2) (25.7) (61.0) (7l)a
aSignificantly different from the first dose P<0.01 (t test of paired samples). For the first dose, blood samples were collected at time (h): 1, 2,
4, 6, 12, 24. At steady state (one month or more), blood samples were obtained at 8 am, before TMX intake.
ND: Not detectable (below limits of sensitivity, see text for values).
Table II Cytosol TMX and metabolite levels
TMX and metabolite concentrations
Receptor status (ngmg- 1 DNA)
Patient ER PR TMX 4 OHT NDT Y Z
(material) (fmolml- 1 protein)
FAG (breast tumour) 5 25 16.8 22.4 95.3 ND 53.2
MAU (breast tumour) 35 0 ND ND ND ND ND
UNT (breast tumour) 5 0 28.1 ND 131.8 ND 97.7
AUG (ascitic cells) 0 0 6.8 8.6 ND ND ND
(Breast =primary)
PAP (breast tumour) 0 0 95.6 ND 227.8 ND 85.2
Steroid receptors measured before initiation of treatment as previously described (Milano et al.,
1983). Biopsies for drug measurement were obtained 8 days after initiation of TMX treatment (30
mgday-1 orally). Cytosol was extracted, like plasma, by diethyl ether after spiking with internal
standard.
ND-Not detectable (below limits of sensitivity, see text for values).512 G. MILANO et al.
column UV photocyclisation and fluorescence detection
(Brown et al., 1983; Camaggi et al., 1983). The optimal
analytical conditions described herein allowed complete
separation and quantification of TMX from all of the
metabolites that have been reported until now in humans
(Furr & Jordan, 1984). The resulting high sensitivity made
possible a limit of detection in plasma in the range of
2 ngml-1 for a small extracted volume (500p1), thereby
allowing acceptable blood sampling for repeated pharmaco-
kinetic studies. In addition, cytosol measurements of TMX
and metabolites were possible for breast cancer patients
under treatment. Other workers, using a sophisticated gas
chromatography mass spectrometry method, failed to detect
4OHT in cytosol (Daniel et al., 1981). Application of the
present method to blood monitoring and cytosol measure-
ment of TMX and metabolites warrants several comments.
(a) The relative proportions of NDT and TMX systemati-
cally reversed between the administration of the first drug
dose and the pseudo-steady state (1 month or more of
continuous oral treatment). This fact was reported previously
(Fabian et al., 1980; Wilkinson et al., 1980; Kemp et al.,
1983), but had not been quantified so accurately for
individuai patients. This observation may be due to the
longer elimination half-life of the metabolite (Adam et al.,
1980). Enzymatic induction of N-demethylation is another
possible explanation; this hypothesis is supported by the fact
that continuous oral administration of the drug predisposes
to a hepatic first pass effect. Supporting this view, 4OHT,
which was scarcely detectable at the first dose, was present
at the steady state with high intersubject variability. Owing
to the inherent difficulties in separating 40HT and NDT by
classical thin layer chromatography, 4OHT was not
evaluable in previous pharmacokinetic studies (Wilkinson et
al., 1980). The presence of metabolite Z has also been
previously signaled (Kemp et al., 1983), but not quantified in
a series of patients. Present data show that metabolite Z
represents a significant part of the circulating drug profile.
Experimental studies to evaluate its pharmacology and
contribution to the activity of the parent drug appear
justified, as has been done for metabolite Y (Jordan et al.,
1983).
(b) The distribution between the unchanged drug and its
metabolites in cytosol is virtually the same as in plasma,
although greater dispersion occurs in tumours. Metabolite Y
was never detectable. Variability was not linked to the
pretreatment ER content of the tumour cytosol. This obser-
vation confirms the need for more thorough investigations
on the so-called antioestrogen binding sites and their possible
role in drug-related actions. Although a correlation has
recently been reported in animals between the tumour TMX
content and tumoral regression (Daniel et al., 1984), clinical
extrapolation of the present results is beyond the scope of
this paper.
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